Barely Significant
← all excerpts

Update on the management of inflammatory bowel disease: specific role of adalimumab.

Clin Exp Gastroenterol · 2011 · PMC3163921 · PMID 21904462

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantP < 0.001actually significant
At week 52, however, there was a highly significant difference between the two groups (19% vs 0% for adalimumab and placebo, respectively; P < 0.001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.